Adding anti-clotting drugs to stroke care ineffective, clinical trial finds

Clinical trial finds adding anti-clotting drugs to stroke care ineffective; medications did not improve patients’ outcomes, as indicated in The New England Journal of Medicine.


Highlighted Terms

Related News

Adding anti-clotting drugs to stroke care ineffective, clinical trial finds - Scientific Inquirer

A clinical trial led by Opeolu Adeoye, MD, at Washington University School of Medicine in St. Louis found that adding anti-coagulant drugs to thrombolysis treatment did not improve outcomes for stroke patients, as published in The New England Journal of Medicine on Sept. 4.

WashU Medicine finds anti-clotting drugs fail to improve stroke care outcomes

WashU Medicine's MOST trial found anti-clotting drugs argatroban and eptifibatide failed to improve stroke outcomes, leading to higher disability and mortality rates.

Anti-coagulant therapy fails to improve stroke outcomes in major study - News-Medical

A clinical trial led by Dr. Opeolu Adeoye found that adding anti-coagulant drugs argatroban or eptifibatide to thrombolysis treatment did not improve stroke outcomes, with both drugs linked to higher disability and mortality rates. The study, published in The New England Journal of Medicine, concludes that neither drug helps prevent further clots, closing a chapter on their potential use but informing future advances in stroke treatment.

Adding anti-clotting drugs to stroke care ineffective, clinical trial finds

Clinical trial finds adding anti-clotting drugs to stroke care ineffective; medications did not improve patients’ outcomes, as indicated in The New England Journal of Medicine.

© Copyright 2024. All Rights Reserved by MedPath